Searchable abstracts of presentations at key conferences in endocrinology

ea0016p584 | Paediatric endocrinology | ECE2008

Growth hormone deficient children born small-for-gestational-age need higher than replacement dose of hGH for successful treatment

Peter Ferenc , Luczay Andrea , Solyom Eniko , Gellen Balazs , Niederland Tamas , Felszeghy Eniko , Sagodi Laszlo , Solyom Janos , Muzsnai Agota

Growth hormone deficient (GHD) children born small-for-gestational-age (SGA) receive the same hGH dose as the children born with appropriate weight/length for gestational age (AGA). There are very few data on their lower growth response to the usual GH replacement dose. The aim of this multi-centre retrospective study is to analyse the hGH dose dependency of GHD children with SGA.SGA was defined as a birth weight/length below – 2 SD for gestational ...

ea0070aep1064 | Hot topics (including COVID-19) | ECE2020

Pharmacokinetics and pharmacodynamics of macimorelin acetate (AEZS-130) in paediatric patients with suspected growth hormone deficiency (GHD)

Csákváry Violetta , Muzsnai Agota , Raduk Dmitri , Chaychenko Tetyana , Bentz Damholt Birgitte , Bakhtadze Bagci Ekaterine , Teifel Michael , Ammer Nicola

Growth hormone deficiency (GHD) in children is a rare, aetiologically diverse condition that results in growth failure and short stature. Inadequate response to two different growth hormone stimulation tests (GHST) is required for the diagnosis of GHD. Macimorelin acetate, a potent, orally administered growth hormone (GH) secretagogue, is approved by the FDA and EMA for the diagnosis of adult GHD. Study AEZS-130-P01 is the first of two studies to investigate macimorelin acetat...